Placebo d'amiloride, AMILORIDE, AMILORIDE
APHP200042
Phase 2 small_molecule active
Quick answer
Placebo d'amiloride, AMILORIDE, AMILORIDE for Patients treated with lithium carbonate for a bipolar disorder treated for at least 5 years and with a urine concentration defect. is a Phase 2 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pari Pharma GmbH
- Indication
- Patients treated with lithium carbonate for a bipolar disorder treated for at least 5 years and with a urine concentration defect.
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active